To manage dyslipidemia risk associated with Clozapine or Olanzapine, which approaches are recommended?

• A. Lifestyle changes
• B. Switch antipsychotics
• C. Add cholesterol-lowering meds
• D. All of the above

Answer: (D)

Dyslipidemia risk from clozapine or olanzapine comes from the metabolic effects these medicines can provoke, so the most effective approach is to address it on multiple fronts. Start with lifestyle changes because diet, physical activity, and weight management directly improve lipid levels and overall cardiovascular risk, and they set the foundation for any other interventions. If clinically feasible, switching to an antipsychotic with a lower metabolic footprint can reduce the ongoing risk at the source, helping to prevent further lipid elevations and weight gain. When lipids remain elevated or the patient’s cardiovascular risk is high despite lifestyle measures and a feasible switch, adding cholesterol-lowering medication—typically a statin—becomes appropriate to directly lower low-density lipoprotein and overall risk. In practice, this combined strategy—lifestyle optimization, thoughtful consideration of switching when possible, and pharmacologic lipid management—offers the most comprehensive protection, which is why all of the above is the best approach. Monitoring lipid levels and coordinating care among psychiatry, primary care, and cardiometabolic care teams are important throughout.